BrightSpring Health Q2 revenue beats estimates as revenue jumps
BrightSpring Health Q2 revenue beats estimates as revenue jumps
Overview
US home health provider's Q2 revenue grew 23% yr/yr, beating analyst expectations
Q2 net income attributable rose to $84.3 mln from $28.2 mln a year earlier
Company raised full-year 2026 revenue and adjusted EBITDA guidance
Outlook
BrightSpring raises 2026 revenue guidance to $15.1 bln-$15.425 bln, up 17%-19.5%
Company lifts 2026 adjusted EBITDA forecast to $820 mln-$845 mln, up 32.8%-36.8%
Amedisys and LHC branches acquisition expected to add about $35 mln to 2026 adjusted EBITDA
Result Drivers
PHARMACY SOLUTIONS - Co said revenue per prescription rose 22% yr/yr, driving segment revenue growth
GROSS PROFIT PER SCRIPT - Co reported gross profit per script up 28% yr/yr in Pharmacy Solutions segment
HOME HEALTH CARE CENSUS - Provider Services segment saw 54% yr/yr increase in average daily home health care census
Company press release: ID:nGNX5hYZ0p
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $3.87 bln | $3.66 bln (15 Analysts) |
Q2 Net Income |
| $84.3 mln |
|
Q2 Adjusted EBITDA |
| $206 mln |
|
Q2 Gross Profit |
| $493 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Brightspring Health Services Inc is $80.00, about 9.8% above its July 30 closing price of $72.88
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 26 three months ago
Reuters Recommended Reads
July 29 - Option Care Health Q2 revenue beats estimates
July 29 - Waystar Q2 revenue beats analyst expectations
July 28 - Germany's Medios cuts 2026 EBITDA outlook on pharma supply price pressure
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)